AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 127.00 Decreased By ▼ -0.04 (-0.03%)
BOP 6.61 Decreased By ▼ -0.06 (-0.9%)
CNERGY 4.50 Decreased By ▼ -0.01 (-0.22%)
DCL 8.55 No Change ▼ 0.00 (0%)
DFML 41.78 Increased By ▲ 0.34 (0.82%)
DGKC 87.50 Increased By ▲ 0.65 (0.75%)
FCCL 32.59 Increased By ▲ 0.31 (0.96%)
FFBL 64.99 Increased By ▲ 0.19 (0.29%)
FFL 10.33 Increased By ▲ 0.08 (0.78%)
HUBC 109.37 Decreased By ▼ -0.20 (-0.18%)
HUMNL 14.65 Decreased By ▼ -0.03 (-0.2%)
KEL 5.09 Increased By ▲ 0.04 (0.79%)
KOSM 7.56 Increased By ▲ 0.10 (1.34%)
MLCF 41.40 Increased By ▲ 0.02 (0.05%)
NBP 59.61 Decreased By ▼ -0.80 (-1.32%)
OGDC 192.50 Increased By ▲ 2.40 (1.26%)
PAEL 28.20 Increased By ▲ 0.37 (1.33%)
PIBTL 7.79 Decreased By ▼ -0.04 (-0.51%)
PPL 150.99 Increased By ▲ 0.93 (0.62%)
PRL 26.85 Decreased By ▼ -0.03 (-0.11%)
PTC 16.03 Decreased By ▼ -0.04 (-0.25%)
SEARL 86.02 Increased By ▲ 0.02 (0.02%)
TELE 7.83 Increased By ▲ 0.12 (1.56%)
TOMCL 35.40 Decreased By ▼ -0.01 (-0.03%)
TPLP 8.24 Increased By ▲ 0.12 (1.48%)
TREET 16.38 Decreased By ▼ -0.03 (-0.18%)
TRG 53.19 Decreased By ▼ -0.10 (-0.19%)
UNITY 26.35 Increased By ▲ 0.19 (0.73%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
BR100 9,988 Increased By 104.4 (1.06%)
BR30 31,138 Increased By 537.6 (1.76%)
KSE100 94,171 Increased By 815.4 (0.87%)
KSE30 29,184 Increased By 252.8 (0.87%)

WASHINGTON: Pfizer's Covid-19 vaccine is more than 90 percent effective in preventing symptomatic forms of the disease in children aged 5 to 11, the company said in a document released Friday.

The new data were published on the website of the Food and Drug Administration, which has called an advisory panel of independent experts to meet Tuesday to decide whether to authorize the vaccine in this age group.

The analysis was based on around 2,250 trial participants with data accruing until October 8, and most positive cases occurred when the Delta variant was dominant in the US and globally.

"VE (Vaccine Efficacy) against laboratory-confirmed symptomatic Covid-19 occurring at least 7 days after Dose 2 in evaluable participants without evidence of prior SARS-CoV-2 infection was 90.7%," the document said.

Pfizer/BioNTech COVID-19 vaccine effectiveness drops after 6 months

There were no cases of severe Covid and no cases of multisystem inflammatory syndrome in children (MIS-C), a rare but serious post viral condition.

There were no cases of myocarditis or pericarditis (heart inflammation or inflammation around the heart) -- but there are not enough study volunteers to be able to detect highly rare side effects, and male adolescents are thought to be a higher risk group.

This is the first time Pfizer has released an efficacy estimate for its Covid vaccine in younger children. Its earlier press statement only said the shot produced a robust immune response.

Pfizer submits data for COVID-19 vaccine in younger children

The vaccine was tested with a 10 microgram dose, while older age groups have received 30 micrograms.

The administration of President Joe Biden has said it stands ready to roll out shots for the country's 28 million 5 to 11-year-olds as soon as the vaccine is authorized by science agencies.

Comments

Comments are closed.